# Risk of cognitive decline progression is associated to increased blood‐brain‐barrier permeability: A longitudinal study in a memory unit clinical cohort

## TL;DR

This study finds that increased blood-brain barrier permeability is linked to a higher risk of cognitive decline progression in a clinical cohort.

## Contribution

The study identifies blood-brain barrier permeability as a potential biomarker for cognitive decline progression and prognosis.

## Key findings

- An 8% increase in clinical worsening hazard was observed for each 10% increase in blood-brain barrier permeability.
- Vascular cognitive impairment patients had the highest blood-brain barrier permeability levels.
- Male sex, diabetes, and cerebrovascular burden were associated with increased blood-brain barrier permeability.

## Abstract

This study examined the relationship between blood‐brain‐barrier permeability (BBBp), measured by cerebrospinal fluid/serum albumin ratio (QAlb), and cognitive decline progression in a clinical cohort.

This prospective observational study included 334 participants from the BIODEGMAR cohort. Cognitive decline progression was defined as an increase in Global Deterioration Scale and/or Clinical Dementia Rating scores. Associations between BBBp, demographics, and clinical factors were explored.

Male sex, diabetes mellitus, and cerebrovascular burden were associated with increased log‐QAlb. Vascular cognitive impairment patients had the highest log‐QAlb levels. Among the 273 participants with valid follow‐up data, 154 (56.4%) showed cognitive decline progression. An 8% increase in the hazard of clinical worsening was observed for each 10% increase in log‐QAlb.

These results suggest that increased BBBp in individuals with cognitive decline may contribute to clinical worsening, pointing to potential targeted therapies. QAlb could be a useful biomarker for identifying patients with a worse prognosis.